<SEC-DOCUMENT>0001144204-15-046731.txt : 20150806
<SEC-HEADER>0001144204-15-046731.hdr.sgml : 20150806
<ACCEPTANCE-DATETIME>20150806091522
ACCESSION NUMBER:		0001144204-15-046731
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150806
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150806
DATE AS OF CHANGE:		20150806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		151031378

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v417389_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of Earliest Event Reported):
August 6, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt"><U>STAAR Surgical
Company</U></FONT><BR>
<FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Delaware</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="width: 34%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>0-11634</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>95-3797439</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1911 Walker Ave, Monrovia, California <BR>
(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>91016</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
Applicable&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Former name or former address, if changed since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 6, 2015, the Company published
a press release regarding its appointment of Dr. Keith Holliday to serve as Vice President, Research and Development, effective
August 19, 2015. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information furnished herewith pursuant
to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &ldquo;filed&rdquo; for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities
of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless
of any general incorporation language in the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-decoration: underline; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 84%; text-decoration: underline; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press release of the Company dated August 6, 2015.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR Surgical Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">August 6, 2015</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v417389_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 48.75pt; width: 117pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dr. Keith Holliday Named Vice President</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Research and Development for STAAR Surgical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MONROVIA, CA, August 6, 2015</B>--STAAR Surgical Company
(NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, has named
Keith Holliday Ph.D. to the position of Vice President, Research and Development, effective August 19, 2015. In this position he
will lead the company&rsquo;s strategic initiative in building a research and development continuum incorporating STAAR&rsquo;s
proprietary Collamer&reg; material and expanding into new areas of opportunity benefiting myopic, presbyopic and cataract vision
care lenses and delivery systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Dr. Holliday is a visionary R&amp;D leader,&rdquo; said
Caren Mason, President &amp; CEO of STAAR Surgical. &ldquo;His twenty years&rsquo; experience leading teams of scientists, engineers
and clinicians have resulted in new products, new materials and new clinical methodologies that have significantly advanced ophthalmic
care in refractive surgery. Dr. Holliday holds patents in excimer laser beam detection, control and profiling, and methods to correct
presbyopia that synergistically take into account the epithelium&rsquo;s response to corneal inlays. Much of his industrial background
has been involved with optics, including visual pathway analysis and its enhancement using lasers and implants. He is an author
of 37 peer reviewed publications in the scientific literature plus two book chapters and one single-authored book. He is considered
an expert on presbyopia and served as conference chair in 2014 for the International Society of Presbyopia and continues as a committee
member. We are extremely fortunate to have Dr. Holliday join our team and look forward to a new era here at STAAR in research excellence
and development acumen.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Holliday&rsquo;s professional career includes his most recent
position as Vice President, Research and Development at ReVision Optics where he oversaw the development of their corneal inlay
technology that includes a hydrogel inlay for presbyopia correction, delivery devices and clinical methodologies as well as managing
first-in-man clinical studies. Previously, he was Director of Laser Technology at Advanced Medical Optics (AMO) and Staff Laser
Scientist at VISX. Prior to joining VISX, Dr. Holliday worked primarily in academia. He obtained his first degree in Physics and
Electronics from the University of Saint Andrews in Scotland and a Ph.D. from the Laser Physics Centre at the Australian National
University. He spent three years at the Swiss Federal Institute of Technology, where he was primarily involved with the utilization
of optically active polymers and crystals, to develop materials and techniques for very high density, holographic optical storage
and computational systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I am very pleased to be joining STAAR Surgical at this
exciting time as the company is adding to its management team by drawing from the best talent in the ophthalmic industry and beyond,&rdquo;
said Dr. Holliday. &ldquo;Ophthalmology has been an area of incredible innovation for many years and shows no sign of slowing down.
It is my goal to position STAAR at the vanguard of ophthalmic technology drawing on STAAR&rsquo;s material advantages and broadening
into exciting new areas.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>About STAAR Surgical</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR, which has been dedicated solely to ophthalmic surgery
for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All
of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR&rsquo;s lens used in refractive
surgery as an alternative to LASIK is called an Implantable Collamer&reg; Lens or &ldquo;ICL.&rdquo; A lens used to replace the
natural lens after cataract surgery is called an intraocular lens or &ldquo;IOL.&rdquo; More than 500,000 Visian ICLs have been
implanted to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 employees and markets lenses
in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia,
CA. For more information, please visit the Company&rsquo;s website at <FONT STYLE="color: Blue"><U>www.staar.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Safe Harbor</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: statements regarding proposed
prospective products current or future and any statements of assumptions underlying any of the foregoing. Important factors that
could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company&rsquo;s
Annual Report on Form 10-K for the year ended January 2, 2015, under the caption &ldquo;Risk Factors&rdquo;, which is on file with
the Securities and Exchange Commission and available in the &ldquo;Investor Information&rdquo; section of the company&rsquo;s website
under the heading &ldquo;SEC Filings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are based on expectations and assumptions as
of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 20%; padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">CONTACT:</font></td>
    <TD STYLE="width: 40%; padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>Investors</b></font></td>
    <TD STYLE="width: 40%; padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>Media</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">EVC Group</font></td>
    <TD STYLE="padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">EVC Group</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Brian Moore, 310-579-6199</font></td>
    <TD STYLE="padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Rob Swadosh, 212-850-6021</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Doug Sherk, 415-652-9100</font></td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "5 68# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W2>XEM?F=
M \7=AQCZ_P"0/>EBU"VED$7F;)3R(Y/E8_3U'N,BK59%]I),;&T2*1"<M:3#
M,;'U7^X?<<>W>D[K89KT5REI-<-*T.F7SP7,?WM.U#YL?[K=<?0FISXJ>PD$
M6LZ=/:,>!(GSQG\?_P!=+G74?*SI**J6>J6&H+FTNXI?96Y'X=:MU1(4444
M%%%% !5=91_:,D.>?*5OU858K%CN@?&<UMGI9*?QWG_&DW8:-JBBBF(****
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M[:(3=O4JZ7I-II-OY5LGS-R\C<LY]2:O445JE8@**** "BBB@ HHHH ****
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M=8__ $*LOX-_\B_J'_7U_P"R"M3XI_\ (BW'_76/_P!"K+^#?_(OZA_U]?\
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MKGTFN9/$M]9OJ$T=O%"LB !/E)Z\E:&[ D=!16-X?U"YOA>I,XFC@G,<5P%
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MU<V.A2W5K.T4L97! !SE@.<CWK8C4I&JEV<@?>;&3^5%];#L.HHHIB"BBB@
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
